Cited 17 times in
Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 황호경 | - |
dc.date.accessioned | 2023-08-09T02:32:43Z | - |
dc.date.available | 2023-08-09T02:32:43Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195622 | - |
dc.description.abstract | Background: Cervical cancer is a world-wide problem that requires transformative therapeutic strategies. We have previously developed patient-derived orthotopic xenograft (PDOX) nude-mouse models of this disease. In the present report, we demonstrate that the standard drug, cisplatinum (CDDP), is highly-effective while the new, highly-touted agent, nab-paclitaxel (NAB-PTX) is ineffective. Materials and methods: Cervical PDOX tumors were grown on the cervix of nude mice for 4 weeks after surgical orthotopic implantation (SOI). Tumors were treated with CDDP or NAB-PTX. Results: H&E staining demonstrated that the PDOX tumor recapitulated the original patient tumor. CDDP was highly-effective. One tumor that was treated with CDDP completely regressed. CDDP-treated tumors were smaller (tumor volume ratio: 0.42±0.36) than the control group (tumor volume ratio: 3.47±1.66) (p<0.01). In contrast, NAB-PTX did not show significant efficacy on the cervical cancer PDOX model (tumor volume ratio: 2.85±1.45) (p=0.47). CDDP-treated tumor weight (50±50 mg) was significantly less than control (238±114 mg) (p<0.01). NAB-PTX-treated tumors were not reduced in weight (246±136 mg) compared to control (p=0.91). There were no significant differences in mouse body weight between groups. Histological evaluation demonstrated that CDDP-treated tumors were fibrotic with scattered squamous cell nests compared to control or NAB-PTX-treated tumors. Conclusion: The results of the present study demonstrate the power of PDOX models of cervical cancer to distinguish efficacy of potential therapeutics for individual patients with this disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.relation.isPartOf | ANTICANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Albumins / pharmacology* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antinematodal Agents / pharmacology* | - |
dc.subject.MESH | Cisplatin / pharmacology* | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Resistance, Neoplasm* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mice, Nude | - |
dc.subject.MESH | Paclitaxel / pharmacology* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Tumor Burden / drug effects | - |
dc.subject.MESH | Uterine Cervical Neoplasms / drug therapy* | - |
dc.subject.MESH | Uterine Cervical Neoplasms / pathology | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Takashi Murakami | - |
dc.contributor.googleauthor | Takuya Murata | - |
dc.contributor.googleauthor | Kei Kawaguchi | - |
dc.contributor.googleauthor | Tasuku Kiyuna | - |
dc.contributor.googleauthor | Kentaro Igarashi | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | Yukihiko Hiroshima | - |
dc.contributor.googleauthor | Chihiro Hozumi | - |
dc.contributor.googleauthor | Shin Komatsu | - |
dc.contributor.googleauthor | Takashi Kikuchi | - |
dc.contributor.googleauthor | Thinzar M Lwin | - |
dc.contributor.googleauthor | Jonathan C Delong | - |
dc.contributor.googleauthor | Kentaro Miyake | - |
dc.contributor.googleauthor | Yong Zhang | - |
dc.contributor.googleauthor | Kuniya Tanaka | - |
dc.contributor.googleauthor | Michael Bouvet | - |
dc.contributor.googleauthor | Itaru Endo | - |
dc.contributor.googleauthor | Robert M Hoffman | - |
dc.identifier.doi | 10.21873/anticanres.11289 | - |
dc.contributor.localId | A04497 | - |
dc.relation.journalcode | J00188 | - |
dc.identifier.eissn | 1791-7530 | - |
dc.identifier.pmid | 28011474 | - |
dc.subject.keyword | Cervical cancer | - |
dc.subject.keyword | PDOX | - |
dc.subject.keyword | cispatinum | - |
dc.subject.keyword | drug response | - |
dc.subject.keyword | nab-paclitaxel | - |
dc.subject.keyword | nude mice | - |
dc.subject.keyword | patient-derived othotopic xenograft | - |
dc.contributor.alternativeName | Hwang, Ho Kyoung | - |
dc.contributor.affiliatedAuthor | 황호경 | - |
dc.citation.volume | 37 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 61 | - |
dc.citation.endPage | 65 | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, Vol.37(1) : 61-65, 2017-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.